Author details

Full Name

David A Fruman

Affiliation

ORCID

Career Start Year

1991

Papers

148

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36727438	Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics.		2023
37596643	PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.	Mol Cancer	2023
37553270	The road less traveled: activating an oncogenic kinase.		2023
37956312	Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.	Cancer Res Commun	2023
37145016	The WW domain of IQGAP1 binds directly to the p110Î± catalytic subunit of PI 3-kinase.		2023
37141632	Synthesis of a Complex Brasilicardin Analogue Utilizing a Cobalt-Catalyzed MHAT-Induced Radical Bicyclization Reaction.		2023
36572154	Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.	J Control Release	2023
37124486	Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia.		2023
34737376	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.	Scientific Reports	2021
34278258	Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function.	iScience	2021
34264929	A cross-institutional analysis of the effects of broadening trainee professional development on research productivity.	PLoS Biology	2021
33318657	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.	Br J Cancer	2021
33358111	Targeting the Mevalonate Pathway in Cancer.		2021
34408976	Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia.	Frontiers in Oncology	2021
33277245	YAP-mediated mechanotransduction tunes the macrophage inflammatory response.	Science advances	2020
33288538	A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease.	Journal of Immunology	2020
32620791	Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth.	Nature Communications	2020
30811291	Targeting PI3K-Gamma in Non-Hodgkin Lymphoma.	Journal of Clinical Oncology	2019
30530594	The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes.	J Immunol	2019
29543389	The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells.	Stem cells translational medicine	2018
29899021	Statins enhance efficacy of venetoclax in blood cancers.	Sci Transl Med	2018
29720560	Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.	Mol Cancer Ther	2018
29487712	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.	Oncotarget	2018
29464092	mTOR inhibition enhances efficacy of dasatinib in -rearranged Ph-like B-ALL.	Oncotarget	2018
27784673	Silencing c-Myc translation as a therapeutic strategy through targeting PI3KÎ´ and CK1Îµ in hematological malignancies.	Blood	2017
28802037	The PI3K Pathway in Human Disease.	Cell	2017
28713374	The Selective Phosphoinoside-3-Kinase p110Î´ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.	Frontiers in Immunology	2017
28569734	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.	J Clin Invest	2017
28363934	Positive and negative roles of p85Î± and p85Î² regulatory subunits of phosphoinositide 3-kinase in insulin signaling.	Journal of Biological Chemistry	2017
28566433	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph and Ph-like B-ALL.	Molecular Cancer Therapeutics	2017
28199308	Cancer: A targeted treatment with off-target risks.	Nature	2017
27613697	Context-Specific Function of S6K2 in Th Cell Differentiation.	Journal of Immunology	2016
27391151	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.	Oncotarget	2016
27245614	The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes.	Sci Signal	2016
26805380	Targeting mTOR for the treatment of B cell malignancies.	British Journal of Clinical Pharmacology	2016
27257176	mTOR signaling: new networks for ALL.	Blood	2016
27472284	Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.	ACS Nano	2016
26152921	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.	Cancer Discovery	2015
25576920	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.	Oncotarget	2015
26460954	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.	Oncotarget	2015
24620870	Idelalisib--a PI3KÎ´ inhibitor for B-cell cancers.	New England Journal of Medicine	2014
25385646	mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2014
24481312	PI3K and cancer: lessons, challenges and opportunities.	Nature Reviews Drug Discovery	2014
24915189	Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.	PLoS ONE	2014
24586420	Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.	PLoS ONE	2014
24803415	DNA-scaffolded multivalent ligands to modulate cell function.	Chembiochem	2014
25133419	Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling.	Journal of Clinical Investigation	2014
23737503	Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.	Proc Natl Acad Sci U S A	2013
24044994	A polyvalent aptamer system for targeted drug delivery.	Biomaterials	2013
24233715	Genetics. Can cancer drugs treat immunodeficiency?	Science	2013